SEREVENT SUMMARY
SEREVENTŪ (salmeterol xinafoate) Inhalation Aerosol Bronchodilator Aerosol For Oral Inhalation Only
SEREVENT (salmeterol xinafoate) Inhalation Aerosol contains salmeterol xinafoate as the racemic form of the 1-hydroxy-2-naphthoic acid salt of salmeterol. The active component of the formulation is salmeterol base, a highly selective beta2-adrenergic bronchodilator.
SEREVENT (salmeterol xinafoate) Inhalation Aerosol is indicated for the following:
Asthma
SEREVENT Inhalation Aerosol is indicated for long-term, twice-daily (morning and evening) administration in the maintenance treatment of asthma and in the prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma, who require regular treatment with inhaled, short-acting beta2-agonists. It should not be used in patients whose asthma can be managed by occasional use of inhaled, short-acting beta2-agonists.
SEREVENT Inhalation Aerosol may be used alone or in combination with inhaled or systemic corticosteroid therapy.
SEREVENT Inhalation Aerosol is also indicated for prevention of exercise-induced bronchospasm in patients 12 years of age and older.
Chronic Obstructive Pulmonary Disease
SEREVENT Inhalation Aerosol is indicated for long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
|